Доступен для скачивания новый гайд по артериальной гипертензии 2007.
[
Ссылки доступны только зарегистрированным пользователям ]
The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
После регистрации доступ бесплатный
При беглом просмотре обращает на себя внмание позиция по Б-адреноблокаторам:
1. "4.4.5
Trials with b-blockers
The benefit of b-blockers compared with that of other antihypertensive agents has recently been questioned on the basis of the results of two large randomized trials, the LIFE study [332] and the ASCOT study [330], both of
which showed superiority of an angiotensin receptor antagonist and, respectively, a calcium antagonist over therapy initiated by a b-blocker as far as stroke (LIFE) or stroke and mortality (ASCOT) were concerned. These
two large trials have strongly influenced a recent metaanalysis [343] which concluded that b-blocker initiated therapy is inferior to others in stroke prevention, but not in prevention of myocardial infarction and reduction in
mortality.."
2. "These conclusions must be considered with care but also with a critical mind"
3. "In any case, the above quoted meta-analyses of b-blocker initiated trials [297,343] well illustrate the difficulties inherent in many recent trials in which combination therapy hinders the attribution of either benefits or harms
to individual compounds."
И вообще, много всего интересного
